GALDERMA GRP AG
185,00€
-2,00 (-1,07%)
20.07.2026, 09:33:36 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +46,14 +0,19% 24.877,12
- MDAX ® -175,10 -0,55% 31.864,73
- TecDAX ® -11,93 -0,32% 3.770,35
- E-STOXX 50 ® -52,74 -0,84% 6.230,87
- NASDAQ 100 -433,11 -1,49% 28.592,66
- HANG SENG +550,39 +2,24% 25.112,63
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 187,00€ | -1,07% |
| 1 Woche | 187,00€ | ±0,00% |
| 1 Monat | 186,00€ | +0,54% |
| 6 Monate | -- | -- |
| Lfd. Jahr (YTD) | -- | -- |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 185,00€ |
| Schluss Vortag | 187,00€ |
| Eröffnung | 186,00€ |
| Geld | 186,00€ |
| Brief | 186,00€ |
| Tages-Hoch | 186,00€ |
| Tages-Tief | 185,00€ |
| 52 Wochen-Hoch | 204,00€ |
| 52 Wochen-Tief | 149,00€ |
| Allzeit-Hoch | 204,00€ |
| Allzeit-Tief | 149,00€ |
Nachrichten
- BUSINESS WIRE: Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region - 20.07.2026, 07:00:03 Uhr
- BUSINESS WIRE: Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns - 07.07.2026, 07:00:06 Uhr
- BUSINESS WIRE: Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States - 01.07.2026, 07:00:07 Uhr
- BUSINESS WIRE: Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments - 11.06.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch - 22.05.2026, 18:25:04 Uhr
- BUSINESS WIRE: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - 23.04.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Shareholders Approve All Annual General Meeting Proposals - 22.04.2026, 17:45:02 Uhr
- BUSINESS WIRE: Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform - 16.04.2026, 07:00:02 Uhr
- BUSINESS WIRE: Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause - 09.04.2026, 07:00:05 Uhr
- BUSINESS WIRE: AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis - 28.03.2026, 16:00:03 Uhr
